NASDAQ:CYRX

Cryoport Competitors

$52.29
-1.64 (-3.04 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$50.70
Now: $52.29
$53.82
50-Day Range
$48.50
MA: $55.36
$66.14
52-Week Range
$15.90
Now: $52.29
$84.97
Volume280,590 shs
Average Volume662,185 shs
Market Capitalization$2.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.23

Competitors

Cryoport (NASDAQ:CYRX) Vs. JAZZ, UTHR, MRVI, MRTX, BBIO, and RARE

Should you be buying CYRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Cryoport, including Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Maravai LifeSciences (MRVI), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), and Ultragenyx Pharmaceutical (RARE).

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Cryoport (NASDAQ:CYRX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Valuation and Earnings

This table compares Jazz Pharmaceuticals and Cryoport's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.21$523.37 million$14.6011.05
Cryoport$33.94 million70.26$-18,330,000.00($0.55)-95.07

Jazz Pharmaceuticals has higher revenue and earnings than Cryoport. Cryoport is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.7% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 88.3% of Cryoport shares are held by institutional investors. 4.6% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 11.5% of Cryoport shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Jazz Pharmaceuticals and Cryoport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Cryoport-55.87%-17.68%-11.32%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Jazz Pharmaceuticals and Cryoport, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111502.82
Cryoport00703.00

Jazz Pharmaceuticals presently has a consensus price target of $185.8824, indicating a potential upside of 15.17%. Cryoport has a consensus price target of $72.00, indicating a potential upside of 37.69%. Given Cryoport's stronger consensus rating and higher probable upside, analysts plainly believe Cryoport is more favorable than Jazz Pharmaceuticals.

Volatility and Risk

Jazz Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Summary

Jazz Pharmaceuticals beats Cryoport on 9 of the 14 factors compared between the two stocks.

United Therapeutics (NASDAQ:UTHR) and Cryoport (NASDAQ:CYRX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Valuation and Earnings

This table compares United Therapeutics and Cryoport's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$1.45 billion6.25$-104,500,000.00($2.39)-85.09
Cryoport$33.94 million70.26$-18,330,000.00($0.55)-95.07

Cryoport has lower revenue, but higher earnings than United Therapeutics. Cryoport is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

90.1% of United Therapeutics shares are held by institutional investors. Comparatively, 88.3% of Cryoport shares are held by institutional investors. 10.9% of United Therapeutics shares are held by company insiders. Comparatively, 11.5% of Cryoport shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares United Therapeutics and Cryoport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United Therapeutics33.25%15.48%11.31%
Cryoport-55.87%-17.68%-11.32%

Analyst Ratings

This is a summary of recent ratings and recommmendations for United Therapeutics and Cryoport, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United Therapeutics00703.00
Cryoport00703.00

United Therapeutics presently has a consensus price target of $219.5714, indicating a potential upside of 7.97%. Cryoport has a consensus price target of $72.00, indicating a potential upside of 37.69%. Given Cryoport's higher probable upside, analysts plainly believe Cryoport is more favorable than United Therapeutics.

Volatility and Risk

United Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Maravai LifeSciences (NASDAQ:MRVI) and Cryoport (NASDAQ:CYRX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Maravai LifeSciences and Cryoport, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
Cryoport00703.00

Maravai LifeSciences presently has a consensus price target of $38.1250, indicating a potential upside of 10.00%. Cryoport has a consensus price target of $72.00, indicating a potential upside of 37.69%. Given Cryoport's higher probable upside, analysts plainly believe Cryoport is more favorable than Maravai LifeSciences.

Valuation and Earnings

This table compares Maravai LifeSciences and Cryoport's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
Cryoport$33.94 million70.26$-18,330,000.00($0.55)-95.07

Maravai LifeSciences has higher earnings, but lower revenue than Cryoport.

Institutional and Insider Ownership

88.3% of Cryoport shares are held by institutional investors. 11.5% of Cryoport shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Maravai LifeSciences and Cryoport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
Cryoport-55.87%-17.68%-11.32%

Cryoport (NASDAQ:CYRX) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap transportation companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Cryoport and Mirati Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryoport00703.00
Mirati Therapeutics151002.56

Cryoport presently has a consensus target price of $72.00, indicating a potential upside of 37.69%. Mirati Therapeutics has a consensus target price of $218.5714, indicating a potential upside of 28.44%. Given Cryoport's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cryoport is more favorable than Mirati Therapeutics.

Valuation & Earnings

This table compares Cryoport and Mirati Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryoport$33.94 million70.26$-18,330,000.00($0.55)-95.07
Mirati Therapeutics$3.34 million2,579.76$-213,260,000.00($5.69)-29.91

Cryoport has higher revenue and earnings than Mirati Therapeutics. Cryoport is trading at a lower price-to-earnings ratio than Mirati Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

88.3% of Cryoport shares are owned by institutional investors. Comparatively, 94.9% of Mirati Therapeutics shares are owned by institutional investors. 11.5% of Cryoport shares are owned by company insiders. Comparatively, 4.1% of Mirati Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Cryoport has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.

Profitability

This table compares Cryoport and Mirati Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cryoport-55.87%-17.68%-11.32%
Mirati TherapeuticsN/A-60.01%-54.21%

Summary

Cryoport beats Mirati Therapeutics on 8 of the 14 factors compared between the two stocks.

Cryoport (NASDAQ:CYRX) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap transportation companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Cryoport and BridgeBio Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryoport00703.00
BridgeBio Pharma01902.90

Cryoport presently has a consensus target price of $72.00, indicating a potential upside of 37.69%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 33.77%. Given Cryoport's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cryoport is more favorable than BridgeBio Pharma.

Valuation & Earnings

This table compares Cryoport and BridgeBio Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryoport$33.94 million70.26$-18,330,000.00($0.55)-95.07
BridgeBio Pharma$40.56 million200.11$-260,590,000.00($2.48)-21.97

Cryoport has higher earnings, but lower revenue than BridgeBio Pharma. Cryoport is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

88.3% of Cryoport shares are owned by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are owned by institutional investors. 11.5% of Cryoport shares are owned by company insiders. Comparatively, 40.3% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Cryoport has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.

Profitability

This table compares Cryoport and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cryoport-55.87%-17.68%-11.32%
BridgeBio PharmaN/A-109.88%-48.54%

Cryoport (NASDAQ:CYRX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap transportation companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Cryoport and Ultragenyx Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryoport00703.00
Ultragenyx Pharmaceutical06802.57

Cryoport presently has a consensus target price of $72.00, indicating a potential upside of 37.69%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, indicating a potential upside of 26.79%. Given Cryoport's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cryoport is more favorable than Ultragenyx Pharmaceutical.

Valuation & Earnings

This table compares Cryoport and Ultragenyx Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryoport$33.94 million70.26$-18,330,000.00($0.55)-95.07
Ultragenyx Pharmaceutical$103.71 million66.80$-402,730,000.00($7.36)-14.06

Cryoport has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Cryoport is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

88.3% of Cryoport shares are owned by institutional investors. 11.5% of Cryoport shares are owned by company insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Cryoport has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500.

Profitability

This table compares Cryoport and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cryoport-55.87%-17.68%-11.32%
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%

Summary

Cryoport beats Ultragenyx Pharmaceutical on 10 of the 14 factors compared between the two stocks.


Cryoport Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$161.40-0.3%$9.09 billion$2.16 billion50.91Insider Selling
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.36-1.3%$9.06 billion$1.45 billion19.24Analyst Report
Analyst Revision
News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$34.66-4.1%$8.93 billionN/A0.00Analyst Downgrade
News Coverage
Gap Up
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$170.17-1.8%$8.62 billion$3.34 million-22.10Insider Selling
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.49-6.7%$8.12 billion$40.56 million-15.98Analyst Report
Gap Down
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$103.48-3.0%$6.93 billion$103.71 million-23.57News Coverage
Gap Down
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$217.93-0.0%$6.83 billion$311.33 million-126.70Insider Selling
News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$125.61-3.1%$6.75 billion$14.98 million-15.30Gap Down
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$62.15-2.5%$6.45 billion$87.99 million-73.99News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.79-4.3%$6.30 billion$150,000.00-21.13News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36-0.8%$5.97 billion$1.12 billion88.25
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.54-1.3%$5.60 billion$380.83 million-9.02
Allakos logo
ALLK
Allakos
1.7$105.00-2.9%$5.58 billionN/A-38.32Insider Selling
Gap Down
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.16-0.1%$5.46 billion$66.51 million17.37
Perrigo logo
PRGO
Perrigo
2.5$40.53-0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.5$73.90-4.1%$5.17 billion$85.54 million0.00Insider Selling
Gap Down
Galapagos logo
GLPG
Galapagos
1.3$77.81-0.1%$5.10 billion$1.00 billion-11.79
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$56.51-0.5%$4.68 billionN/A0.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61-0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39-2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
News Coverage
Gap Down
LEGN
Legend Biotech
1.2$28.45-6.5%$3.76 billion$64.39 million0.00Gap Down
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60News Coverage
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.